2. Academic Validation
  3. Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET

Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET

  • J Cereb Blood Flow Metab. 2020 Jan;40(1):150-162. doi: 10.1177/0271678X18806640.
Viktoria Zoufal 1,  Thomas Wanek 1,  Markus Krohn 2,  Severin Mairinger 1,  Thomas Filip 1,  Michael Sauberer 1,  Johann Stanek 1,  Thomas Pekar 3,  Martin Bauer 4,  Jens Pahnke 2 5 6 7,  Oliver Langer 1 4 8
Affiliations

Affiliations

  • 1 Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria.
  • 2 Department of Neuro/Pathology, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
  • 3 University of Applied Sciences, Wiener Neustadt, Austria.
  • 4 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • 5 LIED, University of Lübeck, Lübeck, Germany.
  • 6 Leibniz-Institute of Plant Biochemistry, Halle, Germany.
  • 7 Department of Pharmacology, University of Latvia, Rīga, Latvia.
  • 8 Department of Biomedical Imaging und Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
PMID: 30354871 DOI: 10.1177/0271678X18806640
Abstract

P-glycoprotein (P-gp, ABCB1) is an efflux transporter at the blood-brain barrier (BBB), which mediates clearance of beta-amyloid (Aβ) from brain into blood. We used (R)-[11C]verapamil PET in combination with partial P-gp inhibition with tariquidar to measure cerebral P-gp function in a beta-amyloidosis mouse model (APPtg) and in control mice at three different ages (50, 200 and 380 days). Following tariquidar pre-treatment (4 mg/kg), whole brain-to-plasma radioactivity concentration ratios (Kp,brain) were significantly higher in APPtg than in wild-type mice aged 50 days, pointing to decreased cerebral P-gp function. Moreover, we found an age-dependent decrease in cerebral P-gp function in both wild-type and APPtg mice of up to -50%. Alterations in P-gp function were more pronounced in Aβ-rich brain regions (hippocampus, cortex) than in a control region with negligible Aβ load (cerebellum). PET results were confirmed by immunohistochemical staining of P-gp in brain microvessels. Our results confirm previous findings of reduced P-gp function in Alzheimer's disease mouse models and show that our PET protocol possesses adequate sensitivity to measure these functional changes in vivo. Our PET protocol may find use in clinical studies to test the efficacy of drugs to induce P-gp function at the human BBB to enhance Aβ clearance.

Keywords

APPPS1 mice; Alzheimer’s disease; P-glycoprotein; beta-amyloid; blood–brain barrier.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z